A Phase II trial of high dose epirubicin in patients with advanced breast carcinoma
Clicks: 184
ID: 271757
2000
BACKGROUND Anthracyclines are among the most active drugs in the treatment of breast carcinoma and exhibit a steep dose‐response curve in vitro. This trial was performed to determine the efficacy and toxicity of epirubicin in the treatment of patients with advanced breast carcinoma when administered as a single agent in maximal doses. METHODS Patients with chemotherapy‐naïve American Joint Committee on Cancer/International Union Against Cancer Stage IIIB or IV breast carcinoma received epirubicin, 180 mg/m2, intravenously every 3 weeks for a maximum of 8 cycles of therapy. Hematopoietic growth factors and cardioprotective agents were not used routinely. RESULTS Twenty‐seven patients were entered in the study. Although NCI/CTC criteria Grade 4 neutropenia occurred in 96% of patients, epirubicin was administered at 83.1% of the planned dose intensity. The median fall in left ventricular ejection fraction was 10%; clinical cardiac toxicity was observed in 3 patients. Objective responses were observed in 21 patients, including 6 complete responses. CONCLUSIONS High dose epirubicin was found to result in substantial hematologic toxicity but was highly active in the treatment of patients with advanced breast carcinoma. Cancer 2000;88:375–80. © 2000 American Cancer Society.
| Reference Key |
sledge2000cancera
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Kathy D. Miller,Nikhil Munshi,David Loesch,Lawrence H. Einhorn M.D.,George W. Sledge;Kathy D. Miller;Nikhil Munshi;David Loesch;Lawrence H. Einhorn M.D.;George W. Sledge; |
| Journal | cancer |
| Year | 2000 |
| DOI | 10.1002/(sici)1097-0142(20000115)88:23.0.co;2-m |
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.